Sponsor:
Rigel Pharmaceuticals
Code:
NCT06161974
Conditions
High Grade Glioma
Astrocytoma
Astrocytoma, Grade III
Astrocytoma, Grade IV
Diffuse Intrinsic Pontine Glioma
Eligibility Criteria
Sex: All
Age: 12 - 39
Healthy Volunteers: Not accepted
Interventions
Olutasidenib + TMZ
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by Rigel Pharmaceuticals on 2025-02-21.